Purinethol, Xaluprine (previously mercaptopurine nova laboratories)(mercaptopurine)
Mercaptopurine, Purinethol, Purixan, Xaluprine (mercaptopurine) is a small molecule pharmaceutical. Mercaptopurine was first approved as Purinethol on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, non-hodgkin lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat lymphoid leukemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Mercaptopurine, Purinethol, Purixan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mercaptopurine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PURIXAN | Nova Laboratories | N-205919 RX | 2014-04-28 | 1 products, RLD, RS |
| PURINETHOL | Stason Pharmaceuticals | N-009053 RX | 1982-01-01 | 1 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mercaptopurine | New Drug Application | 2025-09-08 |
| purixan | New Drug Application | 2025-08-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0108 | Mercaptopurine, oral, 50 mg |
Clinical
Clinical Trials
421 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 19 | 81 | 62 | 17 | 19 | 177 |
| Leukemia | D007938 | — | C95 | 7 | 59 | 50 | 15 | 14 | 135 |
| Lymphoid leukemia | D007945 | — | C91 | 8 | 41 | 29 | 11 | 9 | 91 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 3 | 6 | 15 | 14 | 12 | 47 |
| Lymphoma | D008223 | — | C85.9 | 2 | 17 | 19 | 1 | 1 | 36 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 2 | 4 | 8 | 8 | 22 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | 1 | 5 | 14 | 21 |
| Vasculitis | D014657 | EFO_0006803 | M31 | — | 5 | 8 | 3 | 1 | 16 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 3 | 3 | 5 | 4 | 15 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 4 | 6 | 1 | 3 | 14 |
Show 49 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 11 | 9 | — | 1 | 21 |
| Burkitt lymphoma | D002051 | — | C83.7 | 4 | 10 | 9 | — | — | 20 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 1 | 8 | 6 | — | — | 12 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 2 | 6 | 3 | — | 1 | 10 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 2 | 4 | — | 2 | 9 |
| Myeloid leukemia | D007951 | — | C92 | — | — | 3 | — | 2 | 5 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | 3 | — | — | 5 |
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | — | 3 | 2 | — | — | 5 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | — | 1 | — | 3 | 4 |
| Langerhans-cell histiocytosis | D006646 | — | C96.6 | — | 1 | 4 | — | — | 4 |
Show 33 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute disease | D000208 | — | — | 1 | 2 | — | — | 1 | 4 |
| Neoplasms | D009369 | — | C80 | 3 | 4 | — | — | — | 4 |
| Pemphigus | D010392 | EFO_1000749 | L10 | — | 2 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 2 | — | — | — | 2 |
| Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | 2 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 2 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | — | 1 | — | — | — | 1 |
| Vascular skin diseases | D017445 | — | — | — | 1 | — | — | — | 1 |
| Blastic plasmacytoid dendritic cell neoplasm | D000099067 | — | C86.4 | — | 1 | — | — | — | 1 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | 2 | 3 |
| Dermatitis | D003872 | — | L30.9 | 1 | — | — | — | 2 | 3 |
| Pathologic complete response | D000095384 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Photosensitivity disorders | D010787 | — | L57.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 2 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
| Genetic polymorphism | D011110 | — | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Immune system diseases | D007154 | — | D89.9 | — | — | — | — | 1 | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
| Blood platelet disorders | D001791 | — | — | — | — | — | — | 1 | 1 |
| Hemorrhagic disorders | D006474 | — | D69.9 | — | — | — | — | 1 | 1 |
| Skin manifestations | D012877 | — | — | — | — | — | — | 1 | 1 |
Show 28 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mercaptopurine |
| INN | mercaptopurine |
| Description | Purine-6-thiol is a thiol that is the tautomer of mercaptopurine. It has a role as an antineoplastic agent and an antimetabolite. It is a tautomer of a mercaptopurine. It derives from a hydride of a 7H-purine. |
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O.S=c1[nH]cnc2nc[nH]c12 |
Identifiers
| PDB | — |
| CAS-ID | 6112-76-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200751 |
| ChEBI ID | 31822 |
| PubChem CID | 667490 |
| DrugBank | DB01033 |
| UNII ID | PKK6MUZ20G (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Mercaptopurine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,575 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,235 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use